G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)

NEXT STORY
Global $9.3 Billion Disposable Surgical Devices Market Forecasts to 2028 with COVID-19 Impact Analysis
PREV STORY
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock

DURHAM, N.C., March 23, 2017 (GLOBE NEWSWIRE) -- HEAT BIOLOGICS, INC. (“HEAT”) (NASDAQ:HTBX), a ...

author_avatar
NASDAQ Market News

PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® – GM-CSF Combination to Overcome Tumor Immune Suppression

author_avatar
NASDAQ Market News

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

author_avatar
NASDAQ Market News